Kinerase skincare products is produced by Valeant Pharmaceuticals an international pharmaceutical company. Kinerase consumer skincare products are available worldwide through retailers and their professional line of products are available exclusively through dermatologists, physicians and skin care specialists.
Kinerase skincare was developed from the ingredient Kinetin (N6-furfuryladenine) a plant based antioxidant clinically proven for its healing and anti-aging skin care properties.
Kinerase skincare products produces revolutionary skin care treatments for the repair and rejuvenation of aged skin, diminishing the appearance of wrinkles and fine lines. Kinerase has developed a core line of skin care products as well as the Kinerase Pro Therapy skin care products for more advanced skin care treatments.
Kinerase C8 Peptide Intensive Treatment lotion uses the N8 neuropeptide combined with Kinetin, Vitamin C, Beta-Glucan, Green Tea and Vitamin E for a powerful anti-aging skin care treatment. Kinerase C8 Peptide Intensive Treatment reduces the signs of wrinkles, brightens the skins natural skin tone and boosts collagen reproduction as well as protects the skin from environmental factors and pollutants. Using the same formula Kinerase developed an Intensive Eye Treatment that dramatically transforms the skin around the eyes reducing the look of dark circles and puffiness. Kinerase has clinically proven that using the Intensive Peptide Treatment products can improve the skins overall appearance in 28 days.
Kinerase Skincare products is one of the few skincare companies to develop a product to reduce the appearance of scars, old and new. Kinerase Scar Therapy is a gel formula that uses a patent pending formula that effectively reduces redness and appearance of scars in 4 weeks of use.
Kinerase Skincare products are world renowned skin care therapy solutions for all types of skin and skin conditions. Kinerase products are clinically proven to improve skins overall health by appearing smooth, soft and more youthful looking.